Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 7/2015

01.07.2015 | Original Article

Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma

verfasst von: Karen Chiam, Tingting Wang, David I. Watson, George C. Mayne, Tanya S. Irvine, Tim Bright, Lorelle Smith, Imogen A. White, Joanne M. Bowen, Dorothy Keefe, Sarah K. Thompson, Michael E. Jones, Damian J. Hussey

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The poor prognosis and rising incidence of esophageal adenocarcinoma highlight the need for improved detection methods. The potential for circulating microRNAs (miRNAs) as biomarkers in other cancers has been shown, but circulating miRNAs have not been well characterized in esophageal adenocarcinoma. We investigated whether circulating exosomal miRNAs have potential to discriminate individuals with esophageal adenocarcinoma from healthy controls and non-dysplastic Barrett’s esophagus.

Methods

Seven hundred fifty-eight miRNAs were profiled in serum circulating exosomes from a cohort of 19 healthy controls, 10 individuals with Barrett’s esophagus, and 18 individuals with locally advanced esophageal adenocarcinoma. MiRNA expression was assessed using all possible permutations of miRNA ratios per individual. Four hundred eight miRNA ratios were differentially expressed in individuals with cancer compared to controls and Barrett’s esophagus (Mann-Whitney U test, P < 0.05). The 179/408 ratios discriminated esophageal adenocarcinoma from healthy controls and Barrett’s esophagus (linear regression, P < 0.05; area under receiver operating characteristic (ROC) > 0.7, P < 0.05). A multi-biomarker panel (RNU6-1/miR-16-5p, miR-25-3p/miR-320a, let-7e-5p/miR-15b-5p, miR-30a-5p/miR-324-5p, miR-17-5p/miR-194-5p) demonstrated enhanced specificity and sensitivity (area under ROC = 0.99, 95 % CI 0.96–1.0) over single miRNA ratios to distinguish esophageal adenocarcinoma from controls and Barrett’s esophagus.

Conclusions

This study highlights the potential for serum exosomal miRNAs as biomarkers for the detection of esophageal adenocarcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stavrou, E.P., et al., Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972–2005. Med J Aust, 2009. 191(6): p. 310–4.PubMed Stavrou, E.P., et al., Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972–2005. Med J Aust, 2009. 191(6): p. 310–4.PubMed
2.
Zurück zum Zitat Dubecz, A., et al., Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. J Gastrointest Surg, 2013. Dubecz, A., et al., Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. J Gastrointest Surg, 2013.
3.
Zurück zum Zitat de Jonge, P.J., et al., Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut, 2014. 63(1): p. 191–202.PubMedCrossRef de Jonge, P.J., et al., Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut, 2014. 63(1): p. 191–202.PubMedCrossRef
4.
Zurück zum Zitat Gordon, L.G., et al., Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc, 2014. 79(2): p. 242–56 e6.PubMedCrossRef Gordon, L.G., et al., Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc, 2014. 79(2): p. 242–56 e6.PubMedCrossRef
5.
Zurück zum Zitat Miranda, K.C., et al., A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell, 2006. 126(6): p. 1203–17.PubMedCrossRef Miranda, K.C., et al., A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell, 2006. 126(6): p. 1203–17.PubMedCrossRef
6.
Zurück zum Zitat Sayed, D. and M. Abdellatif, MicroRNAs in development and disease. Physiol Rev, 2011. 91(3): p. 827–87.PubMedCrossRef Sayed, D. and M. Abdellatif, MicroRNAs in development and disease. Physiol Rev, 2011. 91(3): p. 827–87.PubMedCrossRef
7.
Zurück zum Zitat Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008. 105(30): p. 10513–8.PubMedCentralPubMedCrossRef Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008. 105(30): p. 10513–8.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Wang, J., et al., Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules, 2014. 19(2): p. 1912–38.PubMedCrossRef Wang, J., et al., Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules, 2014. 19(2): p. 1912–38.PubMedCrossRef
10.
Zurück zum Zitat Cheng, L., et al., Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles, 2014. 3. Cheng, L., et al., Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles, 2014. 3.
11.
Zurück zum Zitat Koberle, V., et al., Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One, 2013. 8(9): p. e75184.PubMedCentralPubMedCrossRef Koberle, V., et al., Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One, 2013. 8(9): p. e75184.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Tanaka, Y., et al., Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer, 2013. 119(6): p. 1159–67.PubMedCrossRef Tanaka, Y., et al., Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer, 2013. 119(6): p. 1159–67.PubMedCrossRef
14.
Zurück zum Zitat Liao, J., et al., Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci, 2014. 15(9): p. 15530–51.PubMedCentralPubMedCrossRef Liao, J., et al., Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci, 2014. 15(9): p. 15530–51.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Warnecke-Eberz, U., et al., Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Tumour Biol, 2015. Warnecke-Eberz, U., et al., Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Tumour Biol, 2015.
16.
Zurück zum Zitat Zingg, U., et al., Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol, 2011. 18(5): p. 1460–8.PubMedCrossRef Zingg, U., et al., Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol, 2011. 18(5): p. 1460–8.PubMedCrossRef
17.
Zurück zum Zitat Boeri, M., et al., MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A, 2011. 108(9): p. 3713–8.PubMedCentralPubMedCrossRef Boeri, M., et al., MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A, 2011. 108(9): p. 3713–8.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Bansal, A., et al., Feasibility of mcroRNAs as biomarkers for Barrett’s Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol, 2011. 106(6): p. 1055–63.PubMedCrossRef Bansal, A., et al., Feasibility of mcroRNAs as biomarkers for Barrett’s Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol, 2011. 106(6): p. 1055–63.PubMedCrossRef
19.
Zurück zum Zitat Wu, X., et al., MicroRNA expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila), 2013. 6(3): p. 196–205.CrossRef Wu, X., et al., MicroRNA expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila), 2013. 6(3): p. 196–205.CrossRef
20.
Zurück zum Zitat Wijnhoven, B.P., et al., MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg, 2010. 97(6): p. 853–61.PubMedCrossRef Wijnhoven, B.P., et al., MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg, 2010. 97(6): p. 853–61.PubMedCrossRef
21.
Zurück zum Zitat Li, Z., et al., MicroRNA-194 Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Targeting FoxM1. Dig Dis Sci, 2014. 59(9): p. 2145–52.PubMedCrossRef Li, Z., et al., MicroRNA-194 Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Targeting FoxM1. Dig Dis Sci, 2014. 59(9): p. 2145–52.PubMedCrossRef
22.
Zurück zum Zitat Dong, P., et al., MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer, 2011. 10: p. 99.PubMedCentralPubMedCrossRef Dong, P., et al., MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer, 2011. 10: p. 99.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Rahman, M., et al., miR-15b/16-2 regulates factors that promote p53 phosphorylation and augments the DNA damage response following radiation in the lung. J Biol Chem, 2014. 289(38): p. 26406–16.PubMedCrossRef Rahman, M., et al., miR-15b/16-2 regulates factors that promote p53 phosphorylation and augments the DNA damage response following radiation in the lung. J Biol Chem, 2014. 289(38): p. 26406–16.PubMedCrossRef
24.
25.
Zurück zum Zitat Mogilyansky, E. and I. Rigoutsos, The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ, 2013. 20(12): p. 1603–14.PubMedCentralPubMedCrossRef Mogilyansky, E. and I. Rigoutsos, The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ, 2013. 20(12): p. 1603–14.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Sozzi, G., et al., Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol, 2014. 32(8): p. 768–73.PubMedCrossRef Sozzi, G., et al., Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol, 2014. 32(8): p. 768–73.PubMedCrossRef
27.
28.
29.
Zurück zum Zitat Meyer, S.U., M.W. Pfaffl, and S.E. Ulbrich, Normalization strategies for microRNA profiling experiments: a ‘normal’ way to a hidden layer of complexity? Biotechnol Lett, 2010. 32(12): p. 1777–88.PubMedCrossRef Meyer, S.U., M.W. Pfaffl, and S.E. Ulbrich, Normalization strategies for microRNA profiling experiments: a ‘normal’ way to a hidden layer of complexity? Biotechnol Lett, 2010. 32(12): p. 1777–88.PubMedCrossRef
30.
Zurück zum Zitat Quidville, V., et al., Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res, 2013. 73(7): p. 2247–58.PubMedCrossRef Quidville, V., et al., Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res, 2013. 73(7): p. 2247–58.PubMedCrossRef
31.
Zurück zum Zitat Appaiah, H.N., et al., Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res, 2011. 13(5): p. R86.PubMedCentralPubMedCrossRef Appaiah, H.N., et al., Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res, 2011. 13(5): p. R86.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Manterola, L., et al., A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol, 2014. 16(4): p. 520–7.PubMedCentralPubMedCrossRef Manterola, L., et al., A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol, 2014. 16(4): p. 520–7.PubMedCentralPubMedCrossRef
Metadaten
Titel
Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma
verfasst von
Karen Chiam
Tingting Wang
David I. Watson
George C. Mayne
Tanya S. Irvine
Tim Bright
Lorelle Smith
Imogen A. White
Joanne M. Bowen
Dorothy Keefe
Sarah K. Thompson
Michael E. Jones
Damian J. Hussey
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 7/2015
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2829-9

Weitere Artikel der Ausgabe 7/2015

Journal of Gastrointestinal Surgery 7/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.